Immune Checkpoint Inhibitors for Urologic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 10966
Special Issue Editor
Interests: identification of biomarkers for prostate; kidney and bladder cancer; neuroendocrine prostate cancer; PSMA theranostics; upper tract urothelial carcinoma; treatment-resistant urothelial carcinoma; genomics and immunogenomics for urological cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit a manuscript to the Special Issue, “Immune Checkpoint Inhibitors for Urologic Cancers”. Urologic malignancies, including prostate, urothelial, kidney and testicular carcinomas, are increasingly diagnosed in Western countries. Despite advances in definitive therapies, metastatic disease remains lethal. The addition of immune checkpoint inhibitors in the armamentarium of current therapeutic modalities in urothelial and kidney cancers has fueled significant research to elucidate the genomic and immunogenomic context of urologic cancers, biomarkers predictive of clinical outcomes and novel therapeutic combinations.
This Special Issue of Cancers welcomes original research articles and reviews related to all aspects of immune checkpoint inhibitor use in urologic cancers.
We are looking forward to receiving your contributions.
You may choose our Joint Special Issue in Current Oncology.
Sincerely,
Dr. Panagiotis Vlachostergios
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- identification of biomarkers for prostate
- kidney and bladder cancer
- neuroendocrine prostate cancer
- PSMA theranostics
- upper tract urothelial carcinoma
- treatment-resistant urothelial carcinoma
- genomics and immunogenomics for urological cancers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.